Edition:
United Kingdom

Arsanis Inc (ASNS.OQ)

ASNS.OQ on NASDAQ Stock Exchange Global Market

3.20USD
18 Jan 2019
Change (% chg)

$-0.14 (-4.19%)
Prev Close
$3.34
Open
$3.33
Day's High
$3.33
Day's Low
$3.18
Volume
19,874
Avg. Vol
262,309
52-wk High
$27.83
52-wk Low
$1.16

Latest Key Developments (Source: Significant Developments)

Arsanis and X4 Pharmaceuticals agree to merger
Tuesday, 27 Nov 2018 

Nov 27 (Reuters) - Arsanis Inc ::ARSANIS AND X4 PHARMACEUTICALS AGREE TO MERGER.ARSANIS AND X4 PHARMACEUTICALS AGREE TO MERGER.ARSANIS INC - PHASE 3 CLINICAL TRIAL FOR X4P-001, A NOVEL CXCR4 ANTAGONIST, ANTICIPATED TO START 1H 2019.ARSANIS INC - CURRENT X4 PHARMACEUTICALS STOCKHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 70% OF COMBINED COMPANY.ARSANIS INC - MICHAEL P. GRAY HAS BEEN APPOINTED TO POSITION OF PRESIDENT AND CHIEF EXECUTIVE OFFICER, EFFECTIVELY IMMEDIATELY.ARSANIS INC - CURRENT ARSANIS STOCKHOLDERS ARE EXPECTED TO OWN APPROXIMATELY 30% OF COMBINED COMPANY.ARSANIS INC - GRAY SUCCEEDS RENÉ RUSSO.ARSANIS INC - PAULA RAGAN, X4 PHARMACEUTICALS' CHIEF EXECUTIVE OFFICER, IS EXPECTED TO OF COMBINED CO CEO.ARSANIS INC - RUSSO WILL REMAIN ON ARSANIS BOARD OF DIRECTORS.ARSANIS INC - BOARD EXPECTED TO BE COMPRISED OF SEVEN DIRECTORS, INCLUDING RENE RUSSO AND DAVID MCGIRR, BOTH CURRENTLY SERVING ON CO' BOARD.ARSANIS INC - TRANSACTION HAS BEEN APPROVED BY BOARD OF BOTH COS.ARSANIS INC - MERGER WOULD RESULT IN A COMBINED COMPANY OPERATING UNDER X4 PHARMACEUTICALS NAME.ARSANIS INC - X4 PHARMACEUTICALS IS EXPECTED TO MERGE WITH A WHOLLY-OWNED SUBSIDIARY OF ARSANIS IN AN ALL-STOCK TRANSACTION.ARSANIS INC - GRAY WILL CONTINUE TO SERVE IN HIS EXISTING ROLE AS CFO.ARSANIS INC - X4 EXPRESSED INTEREST IN RETAINING CERTAIN MEMBERS OF CLINICAL DEVELOPMENT AND REGULATORY STAFF, SCIENTIFIC TEAM IN VIENNA.  Full Article

Arsanis Q3 Loss Per Share $0.76
Friday, 9 Nov 2018 

Nov 9 (Reuters) - Arsanis Inc ::ARSANIS REPORTS FINANCIAL RESULTS FOR THIRD QUARTER 2018.Q3 LOSS PER SHARE $0.76.ANTICIPATES THAT IT WILL SUBSTANTIALLY COMPLETE IMPLEMENTATION OF REDUCTION IN WORKFORCE BY END OF Q4 OF 2018.ESTIMATES THAT IT WILL INCUR TOTAL EXPENSES OF ABOUT $2.8 MILLION RELATING TO REDUCTION IN WORKFORCE DURING Q4 OF 2018 AND Q1 OF 2019.  Full Article

Arsanis Says Phase 2 Clinical Trial Of ASN100 Unlikely To Meet Primary Efficacy Endpoint
Thursday, 28 Jun 2018 

June 28 (Reuters) - Arsanis Inc ::ARSANIS PROVIDES UPDATE FOLLOWING COMPLETION OF PLANNED INTERIM ANALYSIS OF PHASE 2 CLINICAL TRIAL OF ASN100.TRIAL UNLIKELY TO MEET PRIMARY EFFICACY ENDPOINT; ARSANIS TO CEASE TRIAL ENROLLMENT AND EVALUATE COMPLETE CLINICAL TRIAL DATASET.ARSANIS TO CONTINUE FOCUS ON DEVELOPMENT OF ASN500 FOR PREVENTION OF RSV INFECTION.  Full Article

Arsanis Posts Qtrly Loss Per Share $0.74
Thursday, 10 May 2018 

May 10 (Reuters) - Arsanis Inc ::ASN100 PHASE 2 TRIAL INTERIM ANALYSIS RESULTS EXPECTED IN LATE JUNE.QTRLY LOSS PER SHARE $0.74.AS OF MARCH 31, 2018, OUR CASH AND CASH EQUIVALENTS TOTALED $64.0 MILLION.  Full Article

Arsanis Inc - Out Licenses Preclinical Stage E. Coli Monoclonal Antibodies
Wednesday, 4 Apr 2018 

April 4 (Reuters) - Arsanis Inc ::LICENSES PRECLINICAL STAGE E. COLI MONOCLONAL ANTIBODIES.BB100 SECURED EXCLUSIVE,WORLDWIDE PRECLINICAL DEVELOPMENT LICENSE, OPTION TO DEVELOPMENT, COMMERCIALIZATION LICENSE, TO MABS TARGETING E. COLI.  Full Article

Arsanis Reports Q4 Net Loss $1.68 Per Share
Friday, 9 Mar 2018 

March 9 (Reuters) - Arsanis Inc ::ARSANIS REPORTS FINANCIAL RESULTS AND HIGHLIGHTS FOR FOURTH QUARTER AND FULL YEAR 2017.ARSANIS INC - FOR THE FOURTH QUARTER ENDED DECEMBER 31, 2017, ARSANIS REPORTED NET LOSS OF $1.68 LOSS PER SHARE.ARSANIS INC - AS OF DECEMBER 31, 2017, ARSANIS'S CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES AND INVESTMENTS TOTALED $76.8 MILLION.  Full Article

Arsanis Inc Files To Say It Has Raised $20 Million In Equity Financing - SEC Filing
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Arsanis Inc ::ARSANIS INC FILES TO SAY IT HAS RAISED $20 MILLION IN EQUITY FINANCING - SEC FILING.  Full Article

OrbiMed Advisors Reports 13.07 Percent Stake In Arsanis As Of Nov 20 - SEC Filing ‍​
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - OrbiMed Advisors LLC::ORBIMED ADVISORS LLC REPORTS 13.07 PERCENT STAKE IN ARSANIS INC AS OF NOVEMBER 20 - SEC FILING ‍​.ORBIMED ADVISORS LLC - CAUSED OPI IV TO ACQUIRE COMMON STOCK OF THE ARSANIS INC FOR THE PURPOSE OF MAKING AN INVESTMENT.  Full Article

Terrance G. Mcguire Reports A 13.7 Percent Stake In Arsanis Inc As Of November 20, 2017 - SEC Filig
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - Arsanis Inc ::TERRANCE G. MCGUIRE REPORTS A 13.7 PERCENT STAKE IN ARSANIS INC AS OF NOVEMBER 20, 2017 - SEC FILIG.  Full Article

New Enterprise Associates 16 L.P. Reports 14.6 Percent Stake In Arsanis As Of Nov 20
Wednesday, 29 Nov 2017 

Nov 29 (Reuters) - NEW ENTERPRISE ASSOCIATES 16 L.P:NEW ENTERPRISE ASSOCIATES 16 L.P. REPORTS A 14.6 PERCENT STAKE IN ARSANIS AS OF NOVEMBER 20, 2017 - SEC FILING.  Full Article